Department of Pharmacy, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu 223800, China.
Department of General Surgury, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu 223800, China.
Comput Math Methods Med. 2022 Aug 8;2022:4764254. doi: 10.1155/2022/4764254. eCollection 2022.
We investigated the effect of roxadustat on factors associated with renal fibrosis and efficacy. Sixty patients meeting the inclusion criteria between January 2021 and October 2021 were equally distributed into observation (roxadustat) group and control (Erythropoietin) group. Then, the expression of serum hypoxia-inducible factor 1-alpha (HIF-1), transforming growth factor- (TGF-1), vascular endothelial growth factor (VEGF), fibronectin (FN), and collagen Ⅳ (C-IV) was compared at different time points (baseline, 2-week follow-up, and 4-week follow-up). The improvement degree of hemoglobin (Hb) and the change level of iron parameters and hepcidin were also compared between the two groups. In the roxadustat group, the expression of HIF-1 at 2 weeks was significantly higher than the baseline and approached the baseline value at 4 weeks. At 4 weeks, TGF-1 and FN expression was significantly lower than baseline. In addition, the improvement of Hb in the roxadustat group was significantly higher than that in the control group at 4 weeks, and the change of ferritin, transferrin, and hepcidin indexes from baseline was better than in the control group.
After giving roxadustat, it can change the expression of HIF-1, TGF-1, and FN. Its efficacy is superior to EPO, which is worthy of clinical application.
研究罗沙司他对与肾纤维化相关因素及疗效的影响。将 2021 年 1 月至 2021 年 10 月符合纳入标准的 60 例患者等分为观察组（罗沙司他）和对照组（EPO）。比较两组患者不同时间点（基线、2 周随访、4 周随访）血清缺氧诱导因子 1-α（HIF-1）、转化生长因子-β（TGF-β）、血管内皮生长因子（VEGF）、纤维连接蛋白（FN）和Ⅳ型胶原（C-Ⅳ）的表达情况。比较两组血红蛋白（Hb）改善程度和铁参数及铁调素的变化水平。观察组 HIF-1 在治疗 2 周时明显高于基线，并在治疗 4 周时接近基线水平。在治疗 4 周时，TGF-β和 FN 的表达明显低于基线。此外，观察组在治疗 4 周时 Hb 的改善明显高于对照组，且铁蛋白、转铁蛋白和铁调素指数从基线的变化优于对照组。
给予罗沙司他后，可改变 HIF-1、TGF-β和 FN 的表达，其疗效优于 EPO，值得临床应用。
